2022
DOI: 10.1016/j.jval.2022.09.679
|View full text |Cite
|
Sign up to set email alerts
|

EE433 Cost-Effectiveness Analysis of a New Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma in Taiwan: Genetic Test-Based Targeted Therapy of Pemigatinib Versus Chemotherapy of 5-FU

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles